Barotrauma

NEW YORK, March 27, 2024 /PRNewswire/ -- The global acute respiratory distress syndrome treatment market size is estimated to grow by USD 1.22 bn from 2024 to 2028, according to Technavio. The market is estimated to grow at a CAGR of 6.9% during the forecast period. North America held the largest share of the global market in 2023, and the market in the region is estimated to witness an incremental growth of 39%.To understand more about this market- Download a FREE Sample Report in minutes! Continue Reading Technavio has announced its latest market research report titled Global Acute Respiratory Distress Syndrome Treatment Market 2024-2028 Major Players in the Market Numerous companies are capitalizing on this growing trend by implementing strategic measures such as alliances, partnerships, mergers, and acquisitions. Among the notable players in the cheese based snacks market are: Air Liquide SA, Athersys Inc., Boston Scientific Corporation, Dragerwerk AG and Co. KGaA, Getinge AB, Koninklijke Philips N.V., LivaNova PLC, Medtronic, Nihon Kohden Corp., SCHILLER AG, Sleepnet Corp., Stryker Corp., Vyaire Medical Inc., Smiths Group Plc, ResMed Inc., Hamilton Medical AG, GE Healthcare Technologies Inc., Fisher and Paykel Healthcare Corp. Ltd., Edesa Biotech Inc., APEPTICO Forschung und Entwicklung GmbH Analyst Review The Acute Respiratory Distress Syndrome (ARDS) Treatment Market encompasses various interventions aimed at managing this life-threatening condition. ARDS is often triggered by disease prevalence, such as sepsis or pneumonia, which can lead to fluid accumulation in the lungs and cause symptoms like shortness of breath, rapid breathing, and extreme tiredness. Trade regulations play a crucial role in ensuring access to essential treatments, including mechanical ventilation, IV fluids, inhaled medications, nitric oxide, and surfactants. These therapies help manage symptoms, prevent further lung damage, and maintain vital organ function. The rising prevalence of air pollution and exposure to harmful gases further exacerbate the risk of ARDS. The World Health Organization (WHO) emphasizes the importance of addressing these environmental factors to reduce the burden of ARDS and its associated treatment costs, which can be substantial due to the high prices of drugs like inhaled medications and oxygen therapy. Key Market Drivers The Acute Respiratory Distress Syndrome (ARDS) treatment market is experiencing significant growth due to the increasing prevalence of ARDS, driven by sepsis and pneumonia, as well as rising air pollution and harmful gases leading to lung damage. Reimbursement policies in critical care units of hospitals play a crucial role in market expansion, enabling the use of advanced ventilation strategies, such as lung-protective ventilation, which include low tidal volumes, moderate to high PEEP, and driving pressure optimization. These strategies aim to maintain adequate oxygenation while minimizing ventilator-induced lung injury and barotrauma. Treatment costs, including IV fluids, inhaled medications like nitric oxide and surfactants, and mechanical ventilation, continue to be a challenge. Trade regulations and drug prices also impact market revenue growth. The World Health Organization advocates for evidence-based guidelines, which incorporate lung-protective ventilation strategies into clinical practice, optimizing respiratory support and minimizing complications. Market trends include ongoing research and development of new treatments, offering opportunities for growth, while challenges include the high cost of care and the need for personalized treatment approaches. Symptoms of ARDS include low blood pressure, shortness of breath, rapid breathing, and extreme tiredness, emphasizing the importance of effective treatment strategies. Challenges and Opportunities The Acute Respiratory Distress Syndrome (ARDS) treatment market faces a complex competitive landscape due to the heterogeneity of patients. Technological advancements, such as acoustic technology for endotracheal tube occlusion and ventilator strategies, are driving innovation. Healthcare facilities and specialty clinics are key end users, with home healthcare gaining traction. Government awareness campaigns aim to increase disease recognition, yet a lack of awareness persists. Market segmentation considers patient characteristics, including age, sex, comorbidities, and disease etiology. Diagnosis relies on symptoms like shortness of breath, rapid breathing, low blood pressure, and fluid accumulation in the lungs, often caused by sepsis or pneumonia. Approved drugs and reimbursement policies influence treatment costs, which can be high due to critical care unit admissions and hospitalizations. Trade regulations and disease prevalence further shape the market dynamics. Despite these challenges, ongoing research and investment in ARDS treatments offer hope for improving patient outcomes and reducing the burden on vital organs, including the lungs and alveoli. The Acute Respiratory Distress Syndrome (ARDS) Treatment Market is experiencing significant revenue growth due to the rising incidence of extreme tiredness and respiratory distress caused by various factors, including air pollution and harmful gases. Immunomodulatory therapies, such as IV fluids, inhaled medications, nitric oxide, and surfactants, are crucial in managing ARDS. The World Health Organization (WHO) highlights the importance of multimodal treatment approaches, which include anti-inflammatory agents, antiviral therapies, and respiratory support modalities. Market trends include the use of mechanical ventilation, endotracheal tube occlusion, and acoustic technology to optimize treatment outcomes. Growth drivers include research reports, government awareness campaigns, and healthcare investment. Challenges include lack of awareness, end user reimbursement policies, and the competitive landscape. Approved drugs and ventilator strategies are segmented by specialty clinics, home healthcare, and critical care units. Diagnosis and critical care unit admissions are key factors influencing market size. Technological advancements, such as approved drugs and ventilator strategies, offer opportunities for market expansion.To understand more about this market- Download a FREE Sample Report in minutes! Market Overview The Acute Respiratory Distress Syndrome (ARDS) Treatment Market is experiencing significant growth due to the increasing prevalence of ARDS and the need for effective therapeutic interventions. Drugs, such as surfactants and corticosteroids, are commonly used in ARDS treatment. Preventive measures, like oxygen therapy and prone positioning, are also crucial in managing ARDS symptoms. Additionally, advances in technology, such as extracorporeal membrane oxygenation (ECMO), have revolutionized ARDS treatment, offering new hope for patients. The market is further driven by the rising healthcare expenditures and the increasing awareness and education about ARDS. However, the high cost of these treatments and the lack of reimbursement policies pose challenges to the market's growth. Despite these challenges, the market is expected to continue expanding due to the increasing demand for effective ARDS treatments. Table of Contents: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Venodr Landscape 11 Vendor Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

U.S. veterans of the wars in Afghanistan and Iraq who suffered mild traumatic brain injury from exposure to explosive blasts were found to have changes in cerebrospinal fluid proteins that are typically seen in people who develop Alzheimer's disease, according to researchers. U.S. veterans of the wars in Afghanistan and Iraq who suffered mild traumatic brain injury from exposure to explosive blasts were found to have changes in cerebrospinal fluid proteins that are typically seen in people who develop Alzheimer's disease, according to researchers at the University of Washington School of Medicine and VA Puget Sound Health Care System. "While our research does not prove that veterans who experienced these injuries will develop Alzheimer's disease, it raises the possibility that they may be on a pathway leading to dementia," said Dr. Ge Li, the paper's first author and an associate professor of psychiatry and behavioral sciences at UW Medicine. The study was published March 13 in the journal Neurology. Previous research has found that sustaining a moderate to severe TBI increases a person's risk of developing Alzheimer's disease. It is not known, however, whether a mild TBI (mTBI) similarly increases this risk. In the new study, the researchers analyzed protein levels in spinal fluid from 51 U.S. veterans of the wars in Afghanistan and Iraq. Each had suffered mTBIs from exposure to explosive blasts and had an average of 20 blast injuries. Those protein levels were compared with the protein levels of 85 veterans and civilians of similar age who had never sustained a TBI. In this study, the veterans were considered to have experienced a TBI if they had an alteration or loss of consciousness from the blast. The TBIs were considered mild if the loss of consciousness lasted 30 minutes or less and there was no sign of brain damage on standard clinical MRI or CT scan. Such an injury is considered equivalent to a concussion. The researchers examined protein levels in the veterans' cerebrospinal fluid, which flows around and through the brain and carries away waste materials. Two of the proteins measured compose the chief components of amyloid plaques, which aggregate in the brains of people with Alzheimer's. These proteins are called alpha-beta amyloid 40 and 42 (Aβ40, Aβ42). The other proteins are versions of the tau protein. Normally, tau proteins are part of cells' cytoskeletons, which give cells their shape. But with Alzheimer's, these structures are changed, creating tangles within brain cells and killing them. This is the other hallmark of Alzheimer's. With Alzheimer's disease, the levels of alpha-beta amyloid proteins in spinal fluid typically decrease. Researchers hypothesize that the proteins, instead of being flushed out into the spinal fluid and carried away as they normally would be, are deposited in amyloid plaques and remain in the brain. As the disease progresses, tau levels, in contrast, tend to be higher than normal, as the proteins are released from dying brain cells. In the study, mTBI veterans in their late 40s and 50s had lower levels of beta-amyloid proteins, compared with the veterans and civilians who had not had such injuries. Tau protein levels also were abnormal in the older mTBI veterans. Normally, tau levels rise as we age. But among the older middle-aged mTBI veterans, levels tended to remain the same, a finding that the normal brain clearance system may not be working as well in among the people with mTBI. Among older mTBI veterans, having lower beta-amyloid 42 levels was also associated with doing less well on cognitive tests assessing verbal memory and fluency. The decline in beta-amyloid proteins, in particular beta-amyloid 42, was concerning, said senior author Dr. Elaine Peskind, a UW research professor of psychiatry and director of the VA's Northwest Mental Illness Research, Education, and Clinical Center. "A decline in beta-amyloid 42 is the earliest detectable change due to Alzheimer's that can be found in a cognitively normal person," she said. "The change can appear as much as 20 years before symptoms. So a person can have the pathology of Alzheimer's going on in their brain but still not have any symptoms -- no problem with their memory or thinking functions -- for as long as 20 years." Peskind and her collaborators suspect the cause of the changes in the mTBI veterans' spinal fluid proteins is due to blast-related damage to a system in the brain, called the glymphatic system, that allows fluids to flow through the brain and carry away waste products. To find out, they have been funded by the National Institute of Neurological Diseases and Stroke to study the regulation and function of this system in veterans with these injuries.

YouTube Health partnered with Mass General Brigham and the Mexican Red Cross on the informational content. YouTube has launched a new feature to help users quickly find actionable and easy-to-follow videos for basic first aid and emergency care from authoritative health organizations. Viewers searching for certain acute health topics will now see a pinned shelf titled “First aid from health sources” at the top of search results, featuring short explainer videos. YouTube Health partnered with Mass General Brigham and the Mexican Red Cross on the content. The information shelves will appear for topics including opioid overdose, seizure, heart attack, psychosis, CPR, choking, bleeding, stroke, snake bite, tourniquet, suicide and poisoning. They are launching in the U.S. in English and Spanish, with additional countries and languages to come. Mass General Brigham was an early pilot tester of YouTube’s AI-powered dubbing tool called Aloud. It can now share critical health information in Spanish as part of the latest announcement. “Our system is committed to providing credible, trusted information to our patients and, more broadly, to people seeking knowledge around the world,” Merranda Logan, M.D., associate chief academic officer at Mass General Brigham, said in a press release. “We are thrilled to expand our YouTube educational series to include step-by-step basic first aid and emergency care videos in multiple languages.” YouTube Health also worked with the American Heart Association (AHA) to publish a CPR course, available for free on its platform, to help people without a medical background learn CPR. The idea is for viewers to participate in a more in-depth structured learning experience. A Spanish-language version of that course will be available starting in February on the AHA’s channel. Since its launch in 2020, YouTube Health’s mission has been to put high-quality health content at people’s fingertips. Some features to date have ranged from health labels to identify licensed medical professionals to crisis resource panels for viewers in times of distress.